Shares of Lifeward Ltd. (LFWD) surged nearly 75% on Thursday morning after receiving 510(k) FDA clearance for the newest generation of its exoskeleton device, the ReWalk 7.
LFWD is currently trading at $2.5700, up $1.1000 or 74.83%, on the Nasdaq. The stock opened its trading at $1.7400 after closing Wednesday at $1.4700. The stock has traded between $1.2500 and $6.0000 in the past 52-week period.
The seventh generation of the ReWalk, a wearable exoskeleton that allows individuals with spinal cord injury (SCI) to stand and walk again, includes several new features, as well as enhancements and upgrades.
"FDA clearance is a major milestone for our Company and for the industry," said Larry Jasinski, CEO of Lifeward. "For two decades, Lifeward has been committed to providing our users with the most advanced exoskeleton technology and expanding access to all those who can benefit from use of the device. With the ReWalk 7, we are able to deliver on that commitment, and will continue to look for opportunities to innovate and improve upon medical devices for the SCI community."
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.